Journalists can register now for the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, which takes place online on 24-25 October 2020.
The EORTC-NCI-AACR Symposium is at the forefront of meetings about developing cancer drugs for the future. Understanding the pathways and mechanisms that cause cancer and regulate the biological behaviour of tumour cells has led to the development of numerous new agents, ‘designer’ diagnostics, prognostic tests, ‘smart’ drugs, innovative targets for clinical trials and other entirely new ways of tackling cancer.
To bring these developments to patients as quickly and efficiently as possible requires international collaboration, early and optimal exchange of information, good quality translational research, efficient drug development and large prospective clinical trials.
At this Symposium, three of the world’s leading cancer organisations:
- The European Organisation for Research and Treatment of Cancer (EORTC)
- The USA’s National Cancer Institute (NCI)
- The American Association for Cancer Research (AACR)
will join forces in October 2020 to provide a “virtual” platform for presenting recent advances in pre-clinical and clinical research. Around 1,800 international experts in the field will be discussing innovations in drug development, ground-breaking new data, the selection of new targets for anti-cancer drugs, and the impact of new discoveries in molecular biology, in order to improve the survival and quality of life of cancer patients.
The meeting will promote and develop global partnerships in translational research and the 2019 Nobel Prize winner, Sir Peter Ratcliffe
, will deliver the Michel Clavel lecture on Saturday 24 October.
The virtual Symposium and press conferences are open to bona fide representatives of print and electronic media, and registration is free.
NB: the official language of the symposium is English and all press materials will be in English.